SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer

@article{Clamp2006SCOTROC2F,
  title={SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer},
  author={Andrew R. Clamp and Johanna Unelma M{\"a}enp{\"a}{\"a} and Derek Cruickshank and J. Ledermann and Peter M. Wilkinson and Richard S Welch and Stephen Y. T. Chan and Paul A. Vasey and Bengt G{\"o}ran Sorbe and Andrew C Hindley and Gordon C. Jayson},
  journal={British Journal of Cancer},
  year={2006},
  volume={94},
  pages={55 - 61}
}
The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100 mg m−2 (arm A, n=51) or docetaxel 60 mg m−2 with irinotecan 200 mg m−2 (arm B, n=49). Neither arm met the formal feasibility criterion of an eight-cycle treatment… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2004
View 1 Excerpt

Similar Papers

Loading similar papers…